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Abstract Endothelial cells (ECs) secrete numerous bioactive
peptides that are initially synthesized as inactive precursor pro-
teins. One of these, proendothelin-1 (proET-1), undergoes pro-
teolysis at speci¢c pairs of basic amino acids. Here, we wished
to examine the role of mammalian convertases in this event.
Northern blot analysis shows that only furin and PC7 are
expressed in ECs. In vitro cleavage of proET-1 by furin or
PC7 demonstrated that both enzymes e⁄ciently and speci¢cally
process proET-1. These data reveal that furin and PC7 have
similar speci¢cities towards proET-1 and suggest that both
enzymes may participate in the maturation of proET-1 in
ECs. * 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Endothelial cells (ECs) secrete many proteins and peptides
that are necessary for blood pressure homeostasis, coagulation
and immune response. Many of these factors are initially syn-
thesized as precursors and are matured in the constitutive
secretion pathway. One of these, endothelin-1 (ET-1), origi-
nates from a protein of 212 amino acids (human), prepro-
ET-1, which, after removal of the signal peptide, is further
processed at speci¢c basic residues leading to the production
of bigET-1 [1]. This is followed by carboxy-terminal trimming
of basic residues by carboxypeptidases. For the complete con-
version of bigET-1 into biologically active ET-1, cleavage oc-
curs at an unusual motif, Trp73sVal74, by the endothelin-con-
verting enzymes (ECEs) [2]. Thus, processing of proET-1 is a
multi-step process that requires the participation of at least
three proteases in an organized manner.
Over the last 10 years, evidence has revealed that processing
of precursor proteins at motifs such as Lys-Arg, Arg-Arg or
Arg-X-X-Arg is performed by a family of calcium-dependent
serine proteases called subtilisin-like pro-protein convertases
(SPCs) [3^5]. There are presently seven members belonging to
this family: SPC1 (furin/PACE), SPC2 (PC2), SPC3 (PC1/
PC3), SPC4 (PACE4), SPC5 (PC4), SPC6 (PC5/PC6) and
SPC7 (PC7/PC8/LPC). During its processing, a precursor pro-
tein will follow one of two secretory pathways, the constitu-
tive or the regulated pathway and thus could encounter di¡er-
ent subsets of SPCs depending on the cell type and the tissue
in which the precursor is expressed. In the regulated pathway,
SPC2 and SPC3, which are present primarily in neuroendo-
crine and endocrine cells, are thought to be responsible for
processing of numerous peptide precursors [6]. The second
possible route of secretion is the constitutive pathway, in
which a pro-protein could be recognized and cleaved by furin,
SPC4, SPC6 and PC7. The number of mammalian SPCs and
their similar enzymatic speci¢city raise several intriguing ques-
tions as to their potential overlapping or distinct functions in
precursor processing. Functional speci¢city could be deter-
mined by a high degree of substrate speci¢city by each enzyme
and a distinct cellular expression or speci¢c intracellular local-
ization of each SPC. Numerous studies have been carried out
to examine the detailed tissue and cellular distribution of each
SPC in order to co-localize them with various precursor pro-
teins [7^9].
As depicted in Fig. 1, six Arg-X-X-Arg cleavage sites (iden-
ti¢ed as R1a, R1b, R2^R5) within proET-1 are putative rec-
ognition sequences for members of the SPC family. Here, we
show that furin and PC7 are expressed in ECs and that these
enzymes are able to e⁄ciently generate the proper intermedi-
ate peptides necessary for ET-1 production.
2. Materials and methods
2.1. Cell culture
Primary human umbilical vein endothelial cells (HUVECs) were
from Clonetics (San Diego, CA, USA) and were cultured according
to the manufacturer’s protocol. ECV304 cells (human endothelial um-
bilical vein cell line) were grown in M199 medium. BS-C-1 cells (Afri-
can green monkey epithelial-like cell line) and CHO(dhFr3) (Chinese
hamster ovarian cell line de¢cient in dihydrofolate reductase) were
grown in minimal essential medium; COS-7 (African green monkey
¢broblast cell line) and AtT-20 (mouse pituitary adenocarcinoma cell
line) were grown in Dulbecco’s modi¢ed Eagle’s medium; RINm5F
cells (rat pancreatic insulinoma cell line) were cultured in RPMI 1640
medium. All media were supplemented with 10% fetal bovine serum,
50 U/ml penicillin and 50 Wg/ml streptomycin. BS-C-1 cell medium
was also supplemented with 2 mM L-glutamine and 0.1 mM non-
essential amino acids.
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2.2. Northern blot analysis
Total RNA extraction using the guanidine^lithium chloride method
and Northern blotting was performed as previously described [7]. 8 Wg
of total RNA was fractionated on a 1.2% agarose^formaldehyde gel,
transferred to Nytran N membrane (SchleicherpSchuell, Keene, NH,
USA) and probed with 32P-labeled cRNA for each SPC for 18 h,
washed in 0.1% sodium dodecyl sulfate (SDS), 0.1Usaline sodium
citrate, 1 mM EDTA for 3.5 h and exposed on BioMax MS ¢lms
(Eastman Kodak Co., Rochester, NY, USA) for 1^7 days.
2.3. Puri¢cation of recombinant furin and PC7
Puri¢cation of SPC1/714, a truncated form of furin, was performed
as previously described [10] with the following modi¢cations to the
protocol. The ¢rst puri¢cation step was a high performance tangential
£ow ultra¢ltration (Pellicon-II, Millipore, Bedford, MA, USA)
against a 30 kDa molecular weight cuto¡ (mwco) BioMax membrane
(Millipore) where 500 ml of conditioned serum-free medium was con-
centrated to 100^150 ml. The proteins were then reconcentrated by
ultra¢ltration with a Centricon (model 8200, Amicon Inc., Beverly,
MA, USA) against a polyethersulfone membrane, 30 kDa mwco
(Millipore) to 12 ml. This was immediately applied to a HR Sephacryl
S-100 26/60 (Amersham-Pharmacia Biotech.) gel ¢ltration column at a
£ow rate of 0.5 ml/min. The puri¢cation was then resumed according
to the original protocol. PC7v, a truncated secreted form of PC7, was
puri¢ed according to published procedures [11].
2.4. Enzymatic assays and titration
Enzymatic assays were carried out in 100 mM HEPES pH 7.5,
1 mM CaCl2 and 1 mM L-mercaptoethanol with 25 WM of £uorogenic
substrate N-terbutoxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methyl-
coumarine (boc-RVRR-amc) for furin or 20 mM Bis^Tris pH 6.5,
1 mM CaCl2 and 100 WM of pyroglu-Arg-Tyr-Lys-Arg-amc
(p-ERTKR-amc) for PC7. Assays were performed in 0.5 ml at 37‡C
for 30 min for detection of activity or 1 h for kinetic analysis. Reac-
tions were stopped by addition of 0.5 ml of 10 mM EDTA. Reactions
were calibrated with free AMC and £uorescence was measured
(EXV =380 nm, EMV =480 nm). The amount of active enzyme in
the puri¢ed SPC preparations was evaluated by active site titration
with the irreversible decanoyl-Arg-Val-Lys-Arg-chloromethylketone
(dec-RVKR-cmk) inhibitor. The enzyme was incubated with nano-
molar concentrations (0^30 nM) of titrant in 20% dimethyl sulfoxide
in the respective bu¡er of each enzyme in a total volume of 50 Wl and
incubated at 37‡C in 30 min. 100 WM of respective £uorogenic sub-
strate was then added to give a ¢nal volume of 1 ml and reactions
were incubated for 30 min. The reactions were stopped by adding 10 Wl
of 0.5 M of EDTA. Residual £uorescence was measured as described
above.
2.5. Expression and puri¢cation of proET-1 precursors
Histidine-tagged pro-endothelin proteins were produced and puri-
¢ed using the QiaExpress system (Qiagen) as previously reported [12].
Brie£y, JM109 bacteria were grown in 2UYT medium and protein
expression was induced by adding 1.5 mM isopropyl L-D-thiogalacto-
pyranoside. Cells were harvested, centrifuged and lysed in 8 M urea,
0.1 M sodium phosphate, 0.01 M Tris^HCl, pH 8.0. The lysate was
applied to a Ni-NTA column and elution was performed according to
the manufacturer’s instructions. The eluate was then injected into a
high-performance liquid chromatography hydrophobic C4 column
(Vydac, S.P.E. Ltd.) equilibrated with 0.1% v/v tri£uoroacetic acid,
0.05% triethylamine. Proteins were eluted using a 0^80% acetonitrile
gradient in 0.1% v/v tri£uoroacetic acid, 0.05% triethylamine at a £ow
rate of 1 ml and 1%/min. Fractions containing the puri¢ed protein
were dried and reconstituted in 200 mM HEPES pH 7.6.
2.6. In vitro processing by SPCs
200 pmol (5 Wg) of puri¢ed proET-1 was incubated with 1 pmol of
furin or PC7 (¢nal concentration of substrate 4 WM and enzyme
20 nM) in digestion bu¡er (100 mM HEPES pH 7.6, 1 mM CaCl2,
1 mM L-mercaptoethanol and 0.5% Triton X-100 for digestion with
furin and 20 mM Bis^Tris pH 6.5 and 1 mM CaCl2 for PC7) for
various periods of time. The digestion products were analyzed by
16.5% Tris-tricine SDS^PAGE. The gel was stained with GelCode
blue (Pierce Chemical Co., Rockford, IL, USA) or transferred to a
nitrocellulose Optitran membrane for immunoblotting with penta-His
antibody (Qiagen) according to the manufacturer’s protocol.
3. Results
3.1. Presence of furin and PC7 mRNA in ECs
To more fully comprehend the biosynthetic pro¢le of pro-
ET-1 in ECs, we initially focused on establishing the identity
of those SPCs that are present in this cell type. Because of the
exclusive tissue distribution of SPC2 and SPC3 in neuroendo-
crine cells and SPC5 in spermatid cells, we did not pursue
their identi¢cation in ECs. Hence, only furin, SPC4, SPC6
and PC7 were investigated. To detect the presence of the
mRNAs encoding SPCs in two EC lines, we used Northern
blot analysis of total RNA from ECV304 cells and a primary
EC line (HUVECs). As depicted in Fig. 2A, a band at 4.4 kb
was detected after hybridization with a furin cRNA probe in
HUVECs and ECV304 cells and in all of the control cell lines,
consistent with its known ubiquitous distribution [8]. An
hSPC4 cRNA probe revealed a band migrating at 4.4 kb in
COS-7 and RINm5F cells, but not in the HUVECs or
ECV304 cells (Fig. 2B). The 3.5 kb band detected in AtT-20
cells could be one of the multiple known isoforms of SPC4A
[13]. The hSPC6 transcript was not detected by Northern blot
analysis in HUVECs, ECV304, COS-7, RINm5F, AtT-20 and
CHO(dhFr3) cells (Fig. 2C). In Fig. 2D, we detected a speci¢c
3.5 kb band corresponding to PC7 in both ECs. These results
show that both furin and PC7 are expressed in HUVECs and
ECV304 ECs.
3.2. In vitro digestion of proET-1 by furin and PC7
We then compared the e⁄ciency of the two enzymes to
process recombinant proET-1. In order to perform in vitro
digestions of proET-1, su⁄cient quantities of the precursor
as well as the puri¢ed enzymes were produced. To compare
the e⁄ciency of the two enzymes to cleave the ET-1 precursor,
equivalent amounts of enzymes determined by titration with
the irreversible inhibitor dec-RVKR-cmk (data not shown)
were used. Fig. 3A shows the time course of the cleavage
pattern observed after incubation of proET-1 with furin where
four major forms were revealed. Intact recombinant proET-1
(identi¢ed as a) has a theoretical molecular mass of 23 791,
which is in accordance with the molecular weight of 24 kDa
obtained by SDS^PAGE and 23 800 obtained by mass spec-
Fig. 1. Recombinant proET-1. Schematic representation of proET-1
and the potential fragments generated by the cleavage of the various
Arg-X-X-Arg sites (R). Hatched bar indicates active ET-1 moiety
whereas gray portion represents the bigET-1 region. Amino acid
motifs constituting SPC recognition site are indicated. Vertical ar-
rows indicate the putative convertase recognition sites. Black por-
tion represents the His tag epitope. Size of fragments is in kDa.
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trometry (data not shown). After 15 min incubation with fur-
in, we observed a signi¢cant reduction of the undigested pro-
ET-1 and the appearance of shorter polypeptides. The larger
of these (fragment b) corresponds to an N-terminal fragment
when proET-1 is processed at one of the two sites, R4 or R5,
yielding a 18.3 or 19.7 kDa fragment, respectively. Mass spec-
trometry of the digested sample con¢rmed cleavage at R4 due
to the presence of a molecular ion peak at 18 547 (data not
shown). Cleavage at the R2 site produced two fragments, 14.2
and 9.6 kDa (c and d, respectively), also con¢rmed by mass
spectroscopy. We observed a proportional reduction of the
14.2 kDa fragment and an increase of the 12.4 kDa peptide
(identi¢ed as cP) produced after 2 h of incubation, correspond-
ing to the cleavage of the 14.2 kDa fragment at the R3 site.
The 5.0 kDa fragment generated after 2 h corresponds to the
N-terminal fragment (e) after the cleavage of the R1 site.
To further con¢rm the identity of the fragments generated,
we used an anti-His tag antibody and immunoblotting. Since
the His tag is placed at the N-terminal side of proET-1 (see
Fig. 1) only the N-terminal fragments will be detected. As
shown in Fig. 3B, the antibody recognizes the 23.8 (a), the
19.7^18.3 (b) and the 9.6 (d) kDa bands while the 14.2 kDa
fragment (c) is not recognized, enabling us to con¢rm its
identity even if its apparent molecular weight is higher than
its real molecular weight. Since the 5.0 kDa fragment is also
tagged with the His tag, we can con¢rm that it is the
N-terminal fragment generated by the cleavage of the R1
site and not a fragment generated by the cleavage of a
C-terminal site. Thus furin cleaves all furin recognition sites
present in proET-1, albeit with di¡erent e⁄ciencies. The R2
and R4 sites are cleaved preferentially while the R1a or R1b
and R3 sites are less e⁄ciently cleaved.
With an equal concentration of PC7 (20 nM) and identical
experimental conditions, the processing of proET-1 yielded a
similar cleavage pattern as for furin (Fig. 4A). Indeed, we can
detect the 18.3, 14.2 and 9.6 kDa as well as the 5.0 kDa band.
However, PC7’s e⁄ciency to cleave proET-1 was lower than
furin’s since the proET-1 band (a) was still detected up to 2 h
after the start of the incubation, compared to 30 min with
furin. Fig. 4B shows the immunoblot with the anti-His tag
antibody which enabled us to con¢rm the bands generated
with PC7. Again, the antibody recognized the 19.7 or 18.3
and the 9.6 kDa bands as well as the pro-protein. A longer
exposure was necessary to detect the 5.0 kDa band (1 h lane).
In Figs. 3A and 4A we were able to show that both SPCs
cleaved each side of the bigET-1 intermediate (R1 and R2
sites) and therefore should produce a fragment corresponding
to bigET-1 in vivo. However, no fragments with the same
Fig. 2. SPC mRNA expression in cell lines. 8 Wg of total RNA ex-
tracted from di¡erent cell lines was separated on a denaturing aga-
rose gel and transferred to a nylon membrane. The membrane was
then hybridized with human SPC speci¢c probes for furin (A),
SPC4 (B), SPC6 (C) and PC7 (D). The membrane was washed and
exposed on ¢lm for a period of 1^7 days. Molecular weight markers
are in kb.
Fig. 3. Cleavage of proET-1 by furin. A: 5 Wg of proET-1 (4 WM ¢nal) was incubated with 1 pmol of puri¢ed furin (20 nM ¢nal) for di¡erent
periods of time (0.25, 0.5, 1, 2, 4, 8 h). Ensuing samples were analyzed by Tris-tricine 16.5% SDS^PAGE and the gel was stained with GelCode
blue. The commercial bigET-1 and the undigested proET-1 (^) were loaded as control. Molecular weight markers are identi¢ed on the left.
B: Identi¢cation of the N-terminal fragments generated by PC7. Duplicate samples as in (A) were analyzed by immunoblot with anti-His tag
antibody.
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molecular size as bigET-1 were detected. We prolonged the
incubation period of proET-1 with each SPC to 16 h to allow
for the complete digestion and the accumulation of smaller
fragments (Fig. 5). We detected a 4.6 kDa band (identi¢ed by
the arrow, f), possibly corresponding to bigET-1-Lys-Arg.
Western blotting revealed that the anti-His antibody did not
recognize the 4.6 kDa band, ruling out the possibility that it is
an N-terminal fragment (result not shown).
3.3. Processing of proET-1 convertase recognition site mutants
Another approach was used to con¢rm the identity of the
di¡erent bands generated. Production of proET-1 cleavage
site mutants allowed us to further ascertain the identity of
each band. Fig. 6A shows a schematic representation of the
mutants generated. A ¢rst mutant, identi¢ed as R1G, was
constructed by changing Arg49 to Gly (numbering according
to the native preproET-1 protein) in position P4 of the R1b
site. This mutation abolishes both furin recognition sites at
the N-terminus of bigET-1. A second mutant, identi¢ed as
R1GR2G, was constructed by changing Arg89 to Gly of the
R2 site in addition to the R1G mutation. Fig. 6B,C shows
both mutants (R1G and R1GR2G) and the proET-1 WT in-
cubated without or with furin (Fig. 6B) or PC7 (Fig. 6C).
Cleavage of the proET-1/R1G mutant yields the same pro¢le
of cleavage as the proET-1 WT (lane WT, 1 h) except that the
5.0 kDa band (fragment e) is now absent because the R1a/b
site is abolished. The intermediate 14.2 and 9.6 kDa fragments
(fragments c and d) are still generated, demonstrating that the
R1G mutation does not alter the processing of the C-terminal
of bigET-1 (R2 site). When both sites were mutated
(R1GR2G), only the 18.3 kDa fragment (fragment b) is pro-
duced. The identi¢cation of the bands from the mutant pro-
ET-1 was also con¢rmed by Western blotting (results not
shown).
4. Discussion
ECs synthesize precursor proteins, many of which undergo
endoproteolysis, an obligatory step for the production of the
biologically active moieties. The proET-1 precursor contains
many potential recognition sequences for members of the
SPCs. We had previously reported how proET-1 is processed
by furin both in vitro and in vivo at a time when PC7 had not
been identi¢ed [12,14]. In the present work, we have pursued
our characterization of the mammalian convertases found in
ECs and involved in the processing of proET-1. We ¢rst de-
termined by Northern blot analysis which of the convertases
are present in ECs. We detected the presence of two conver-
tases in ECs, namely furin and PC7. The mRNAs were de-
tected in primary HUVECs and in ECV304 cells, an immor-
talized EC line. Both convertases are considered to possess an
ubiquitous tissue distribution. The transcripts encoding SPC4,
SPC6A and SPC6B were not detected in our EC lines. Since
SPC6 had previously been detected in ECs of the aorta by in
situ hybridization [15], it is possible that some ECs found
within the cardiovascular system express SPC6 while others
do not.
Using recombinant enzyme and puri¢ed precursor proteins,
Fig. 4. Cleavage of proET-1 by PC7. A: 5 Wg of proET-1 (4 WM ¢nal) was incubated in the presence of 1 pmol of puri¢ed PC7 (20 nM ¢nal)
in a total volume of 50 Wl for di¡erent periods of time (0.25, 0.5, 1, 2, 4, 8 h). Ensuing samples were analyzed as in Fig. 3A. The commercial
bigET-1 and the undigested proET-1 (^) were loaded as control. B: Identi¢cation of the N-terminal fragments generated by PC7. Duplicate
samples as in (A) were analyzed by immunoblot with anti-His tag antibody.
Fig. 5. Production of bigET-1-Lys-Arg by furin and PC7. 5 Wg of
proET-1 was incubated in a volume of 50 Wl (4 WM ¢nal) in the
presence of 1 pmol of furin or PC7 (20 nM ¢nal) for 16 h and ana-
lyzed on SDS^PAGE as in Fig. 3A. Commercial bigET-1 (Big) was
loaded as a control.
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we established in vitro the ability of each convertase to gen-
erate the appropriate cleavage fragments leading to the pro-
duction of bigET-1-Lys-Arg, an obligatory intermediate in the
biosynthesis of the active ET-1 peptide. The results indicate
that when equal quantities of furin or PC7 are incubated with
proET-1, furin cleaves the precursor with better e⁄ciency
when compared to PC7. Conversely, the pattern of processing
products, as observed by SDS^PAGE, is identical, indicating
that the speci¢city of both enzymes is similar. The order and
time of appearance of the di¡erent peptides shows that the
C-terminus site of the bigET-1 (R2) and the R4 sequence are
preferred recognition sites for both convertases. As previously
noted, cleavage of the R2 site is an important prerequisite for
cleavage by ECE-1 [14]. It is at present unknown whether
cleavage at R4 would yield a biologically active peptide or
whether further cleavage at R5 occurs. Both sites, R4 and
R5, contain optimal convertase recognition sequences with
P4 Arg residues and Ser residues in P1P, signatures often
found in precursors cleaved by furin.
At the N-terminus of the bigET-1, there is a double con-
vertase recognition sequence (R1a/R1b). It is likely that cleav-
age occurs at Arg52 (R1b) instead of Arg49 (R1a) because
cleavage of the latter would yield Ser-Lys-Arg-ET-1 following
processing by ECE. It has been shown that the integrity of the
amino-terminal end of ET-1 is necessary to the biological
activity of the peptide [16]. Furthermore, it is unlikely that
cleavage partitioned between cleavage at R1a and R1b be-
cause digestion of the precursor by furin and chymosin was
shown to result in the generation of an identical pressure
activity on a pharmacological preparation as the one obtained
with the same concentration of synthetic ET-1 [12]. This sug-
gests that furin selectively cleaves the second site (R1b) despite
a P1P Cys residue involved in disul¢de bonding within the
ET-1 peptide. Taken together, the results illustrate how furin
and PC7 possess very similar speci¢cities towards proET-1,
supporting speci¢city studies performed on short £uorogenic
peptides and on precursor proteins [17,18]. Indeed, both en-
zymes show an absolute requirement for arginine in the P1
position. Furin necessitates P4 or P6 arginines while, in addi-
tion, an essential P2 basic residue is needed for PC7. These
requirements may explain the less e⁄cient processing of pro-
ET-1 by PC7 but reconciles the similar e⁄cacy to furin at
cleaving the R2 site that possesses a Lys residue in P2.
ProET-1 is the only member of the endothelin/sarafotoxin
family that contains six potential convertase cleavage sites,
three being located in the C-terminal fragment. ProET-2 con-
tains one cleavage site in its COOH-terminal whereas ET-3
precursor does not. It would be interesting to extend our
Fig. 6. Cleavage of mutant proET-1 by furin or PC7. A: Schematic representation of mutant proET-1. The same legend as in Fig. 1 is used.
Substituted amino acids that generated R1G and R1GR2G mutants are underlined. 5 Wg of proET-1 WT (4 WM ¢nal), mutant R1G or mutant
R1GR2G was incubated for 1 h in a total volume of 50 Wl in the absence (3) or presence of 1 pmol of furin (20 nM ¢nal) (B) or PC7 (C)
and analyzed as in Fig. 3A. Commercial bigET-1 (Big) was loaded as a control.
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¢ndings on the processing of proET-1 to proET-2 and proET-3
since these two precursors have a di¡erent tissue expression
pro¢le and yield ET-related peptides involved in other phys-
iological e¡ects than those associated with ET-1 [19]. They
could be co-localized with other SPCs, especially SPC4, which
is abundantly expressed in the nervous system. SPC4 and
SPC6 might be implicated in the maturation of ET-2 and
ET-3 precursors or even ET-1 outside of the vascular system.
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